CD74
CD74 molecule, major histocompatibility complex, class II invariant chain
CD74; CD74 molecule, major histocompatibility complex, class II invariant chain; II; DHLAG; HLADG; Ia-GAMMA; HLA class II histocompatibility antigen gamma chain; p33; HLA-DR-gamma; MHC HLA-DR gamma chain; Ia-associated invariant chain; gamma chain of class II antigens; HLA-DR antigens-associated invariant chain; CD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated);
HLA-B
major histocompatibility complex, class I, B
HLA-B; major histocompatibility complex, class I, B; ankylosing spondylitis , AS; lymphocyte antigen; MHC class I antigen SHCHA; MHC Class I HLA heavy chain; MHC class I antigen GN00104; leukocyte antigen class I-B; MHC HLA-B cell surface glycoprotein; MH;
OmpA
major outer membrane protein A
ompA;Bacterial outer membrane protein;outer membrane protein A;MOMP;omp1;omp1F;Omp1L1;ompIL2;Chlamydia trachomatis;C. trachomatis;ompIL3;ompIL4;ompIL5;ompIL6;ompIL7;ompIL8;
HLA-DPB1
major histocompatibility complex, class II, DP beta 1
HLA-DPB1; major histocompatibility complex, class II, DP beta 1; HLA DP1B; HLA class II histocompatibility antigen, DP beta 1 chain; MHC HLA DPB1; HLA DP14-beta chain; MHC class II HLA-DRB1; class II HLA beta chain; MHC class II HLA-DP-beta; MHC class II;
HLA-E
major histocompatibility complex, class I, E
HLA-E; major histocompatibility complex, class I, E; HLA class I histocompatibility antigen, alpha chain E; MHC HLA-E alpha-1; lymphocyte antigen; MHC HLA-E alpha-2.1; MHC class I antigen E; HLA class I histocompatibility antigen, E alpha chain; MHC; QA1; EA1.2; EA2.1; HLA-6.2; DKFZp686P19218;
HLA-A
major histocompatibility complex, class I, A
HLA-A; major histocompatibility complex, class I, A; HLA class I histocompatibility antigen, A-1 alpha chain; antigen presenting molecule; leukocyte antigen class I-A; MHC class I antigen HLA-A heavy chain; HLAA; FLJ26655;
HLA-DPA1
major histocompatibility complex, class II, DP alpha 1
T1; HLADP; HLASB; HLA-DP1A; HLA-DPA1; HLA class II histocompatibility antigen, DP alpha 1 chain; DP(W3); DP(W4); MHC class II DPA; HLA-SB alpha chain; OTTHUMP00000029066; MHC class II antigen; MHC class II DP3-alpha; Primed lymphocyte test-4; MHC class IIPA1 antigen; HLA class II histocompatibility antigen, DP alpha chain;
HLA-DQA1
major histocompatibility complex, class II, DQ alpha 1
CD; GSE; DQ-A1; CELIAC1; HLA-DQA; FLJ27088; FLJ27328; MGC149527; HLA-DQA1; HLA class II histocompatibility antigen, DQ alpha 1 chain; HLA-DCA; DC-alpha; DC-1 alpha chain; MHC HLA-DQ alpha; MHC class II DQA1; MHC class II antigen; leucocyte antigen DQA1; MHC class II HLA-DQ-alpha-1; leukocyte antigen alpha chain; MHC class II surface glycoprotein; MHC class II HLA-D alpha glycoprotein; HLA class II histocompatibility antigen, DQ(W3) alpha chain;
HLA-DRA
major histocompatibility complex, class II, DR alpha
MLRW; FLJ51114; HLA-DRA1; HLA-DRA; HLA class II histocompatibility antigen, DR alpha chain; OTTHUMP00000029406; OTTHUMP00000029407; MHC class II antigen DRA; MHC cell surface glycoprotein; histocompatibility antigen HLA-DR alpha; RLA-DR-ALPHA; major histocompatibility complex, class II, DR alpha; ENSOCUG00000009103; chromosome: 12;
HLA-DRB1
major histocompatibility complex, class II, DR beta 1
HLA DRB1; MHC class II antigen HLA DR13; HLA DR13; major histocompatibility complex, class II, DR beta 1;
HLA-DMA
major histocompatibility complex, class II, DM alpha
HLA-DMA; major histocompatibility complex, class II, DM alpha; HLA class II histocompatibility antigen, DM alpha chain; D6S222E; RING6; MHC class II antigen DMA; really interesting new gene 6 protein; class II histocompatibility antigen, M alpha chain; DM;
HLA-DRB4
major histocompatibility complex, class II, DR beta 4
HLA-DRB4; major histocompatibility complex, class II, DR beta 4; HLA DR4B; DR4; DR-4; leukocyte antigen; MHC class2 antigen; MHC HLA DR-beta chain; MHC class II antigen DRB4; DRB1 transplantation antigen; human leucocyte antigen DRB4; MHC class II antigen;
MR1
major histocompatibility complex, class I-related
MR1; major histocompatibility complex, class I-related; HLALS, major histocompatibility complex, class I like sequence; major histocompatibility complex class I-related gene protein; Class I histocompatibility antigen like protein; HLALS; Major histocompatibility complex class I like sequence; Major histocompatibility complex class I related; Major histocompatibility complex class I related isoform CRA a; Major histocompatibility complex class I related isoform CRA c; Major histocompatibility complex class I related isoform CRA d; MHC class I like antigen MR 1; MHC class I like antigen MR1; MHC class I related protein 1 isoform B; MHC class I related protein 1 isoform C; MR 1; Mr1 protein; MR1B; MR1C; OTTHUMP00000033129; OTTHUMP00000033130; OTTHUMP00000033131; MHC class I-like antigen MR-1; MHC class I-related gene protein; MHC class-I related-gene protein; class I histocompatibility antigen-like;
HLA-DMB
major histocompatibility complex, class II, DM beta
HLA-DMB; major histocompatibility complex, class II, DM beta; HLA class II histocompatibility antigen, DM beta chain; D6S221E; RING7; Class II histocompatibility antigen M beta chain; DMB; HLA class II histocompatibility antigen DM beta chain; Major histocompatibility complex class II DM beta; MHC class II antigen DMB; MHC class II antigen HLA DM beta chain; MHC class II HLA DMB; RING 7; OTTHUMP00000029257; OTTHUMP00000178732; MHC class II HLA-DMB; really interesting new gene 7 protein; MHC class II antigen HLA-DM beta chain; class II histocompatibility antigen, M;
HLA-DQB1
major histocompatibility complex, class II, DQ beta 1
CELIAC1; HLA class II histocompatibility antigen, DQ beta 1 chain; HLA DQB; HLA DQB1; IDDM1; Lymphocyte antigen; Major histocompatibility complex class II beta; Major histocompatibility complex, class II, DQ beta 1; MHC class II antigen DQB1; MHC class II antigen HLA DQ beta 1; MHC class II DQ beta chain; MHC class II HLA DQ beta glycoprotein; MHC class2 antigen; MHC DQ beta; OTTHUMP00000029167; OTTHUMP00000178569; OTTHUMP00000178570; OTTHUMP00000178571; HLA-DQB1; DQw1;
HLA-DQB2
major histocompatibility complex, class II, DQ beta 2
HLA-DQB2; major histocompatibility complex, class II, DQ beta 2; HLA DXB; HLA class II histocompatibility antigen, DX beta chain; HLA DQB1; OTTHUMP00000029168; OTTHUMP00000029169; OTTHUMP00000178595; OTTHUMP00000178596; major histocompatibility complex, class II, DQ beta 1; DV19.1 (major histocompatibility complex, class II, DQ beta 2 (HLA-DXB); HLA-DXB; HLA-DQB1;
HLA-G
major histocompatibility complex, class I, G
HLA-G; major histocompatibility complex, class I, G; HLA G histocompatibility antigen, class I, G; HLA class I histocompatibility antigen, alpha chain G; b2 microglobulin; HLA G antigen; HLA class I molecule; MHC class I antigen G; HLA-G histocompatibility antigen, class I, G; MHC-G;
RICTOR
RPTOR independent companion of MTOR, complex 2
RICTOR; RPTOR independent companion of MTOR, complex 2; rapamycin-insensitive companion of mTOR; AVO3; KIAA1999; MGC39830; PIA; pianissimo; rapamycin insensitive companion of mTOR; hAVO3; AVO3 homolog; TORC2-specific protein AVO3; mAVO3; DKFZp686B11164;
CIITA
class II, major histocompatibility complex, transactivator
CIITA; class II, major histocompatibility complex, transactivator; MHC class II transactivator , MHC2TA; MHC class II transactivator; C2TA; NLR family; acid domain containing; NLRA; nucleotide binding oligomerization domain; leucine rich repeat and acid d;
H2-AB1
histocompatibility 2, class II antigen A, beta 1
H2-AB1; histocompatibility 2, class II antigen A, beta 1; Abeta; AI845868; H2 Ab; H2 Ab1; H2 I A beta; Histocompatibility 2 class II antigen A beta 1; Ia2; Iab; MHC class II antigen I A beta 1; Rmcs1; OTTMUSP00000053328; MHC class II H2-IA-beta-psi; MHC class II antigen A beta; response to metastatic cancers 1; major histocompatibility complex class II beta chain; H-2 class II histocompatibility antigen, A be; Ia-2; H-2Ab; H2-Ab; I-Abeta;
H2-D1
histocompatibility 2, D region locus 1
H2-D1; histocompatibility 2, D region locus 1; H-2 class I histocompatibility antigen, L-D alpha chain; Q5k protein; MHC class I H-2Dp; MHC H2-D-q alpha-chain; MHC class I H2 antigen; H-2D cell surface glycoprotein; H2-DC1-beta transplantation antigen pro;
H2-EA-PS
histocompatibility 2, class II antigen E alpha, pseudogene
H2-EA-PS; histocompatibility 2, class II antigen E alpha, pseudogene; AI323765; E alpha f; H 2 class II histocompatibility antigen E D alpha chain; H 2Ea; H2 class II histocompatibility antigen E D alpha chain; H2 Ea; H2 Ea histocompatibility 2 class II antigen E alpha; H2 IE alpha; H2Ea; Histocompatibility 2 class II antigen E alpha; I E alpha MHC class II; Ia 3; Ia3; Major histocompatibility complex H 2E alpha chain; MGC117888; MHC class II antigen E alpha; Ia-3; H-2Ea; H2-Ea; I-Ealpha; E-alpha-f;
H2-K1
histocompatibility 2, K1, K region
H2-K1; histocompatibility 2, K1, K region; H-2 class I histocompatibility antigen, K-W28 alpha chain; H2 class I histocompatibility antigen, KQ alpha chain; H2K; H2K(Q); H2K1; H-2K(B); H-2K(K); H-2K(Q); OTTMUSP00000053300; OTTMUSP00000053302; OTTMUSP00000053303; MHC class I antigen; MHC class I heavy chain H2-K; MHC H2-K transplantation antigen; class I major histocompatibility a; K-f; H-2K; H2-K; H-2K(d);
H2-T23
histocompatibility 2, T region locus 23
H2-T23; histocompatibility 2, T region locus 23; H-2 class I histocompatibility antigen, D-37 alpha chain; H2 T23; H2 class I histocompatibility antigen D37 alpha chain; H2 Q1; Histocompatibility 2 T region locus 23; MHC class I antigen Qa1; MHC classIb Qa1; OTTMUSP00000015895; Qa1; 37b; 37c; Qa-1; T18c; T23b; T23d; Qed-1; H-2T23; H2-Qa1; Qa-1(b); T18c(37);
LOC649783
similar to HLA class II histocompatibility antigen, DRB1-8 beta chain precursor (MHC class I antigen DRB1*8) (DR-8) (DR8) (DRw8)
LOC649783; similar to HLA class II histocompatibility antigen, DRB1-8 beta chain precursor (MHC class I antigen DRB1*8) (DR-8) (DR8) (DRw8);
LOC425256
similar to class II histocompatibility antigen B-L beta chain (clone p14)
similar to class II histocompatibility antigen B-L beta chain (clone p14);
HMHA1
histocompatibility (minor) HA-1
HMHA1; histocompatibility (minor) HA-1; minor histocompatibility protein HA-1; ARHGAP45; HA 1; KIAA0223; HLA HA1; HLA-HA1; Minor histocompatibility antigen HA 1; Minor histocompatibility antigen HA-1; Minor histocompatibility protein HA 1; HA-1;
HLA-DOB
major histocompatibility complex, class II, DO beta
HLA-DOB; major histocompatibility complex, class II, DO beta; HLA class II histocompatibility antigen, DO beta chain; DO beta chain; DOB; DOB_HUMAN; HLA class II histocompatibility antigen; HLA class II histocompatibility antigen DO beta chain; Major histocompatibility complex class II DO beta; Major histocompatibility complex class II DO beta chain; MHC class II antigen DOB;
HLA-DRB5
major histocompatibility complex, class II, DR beta 5
HLA-DRB5; major histocompatibility complex, class II, DR beta 5; DR beta 5 chain; DR 9; DR beta 5; DR beta-5; DR beta5; DR2 beta 2; DR2-beta-2; DR9; DRB5_HUMAN; Dw2; FLJ76359; HLA class II histocompatibility antigen; HLA class II histocompatibility antigen DR beta 5 chain; HLA class II histocompatibility antigen DRB1-9 beta chain; HLA class II histocompatibility antigen, DR-5 beta chain; HLA DRB; Human leucocyte antigen DRB5; Leukocyte antigen class II; Major histocompatibility complex, class II, DR beta 51; MHC class II antigen DRB1*9; MHC class II antigen DRB5; MHC class II HLA beta chain; MHC HLA-DR-beta cell surface glycoprotein; MHC HLA-DR-beta chain; DR-9; HLA class II histocompatibility antigen, DR beta 5 chain; HLA class II histocompatibility antigen, DRB1-9 beta chain; HLA-DRB;
HLA-F
major histocompatibility complex, class I, F
HLA-F; major histocompatibility complex, class I, F; HLA class I histocompatibility antigen, alpha chain F; alpha chain F; CDA12; HLA 5.4; HLA class I histocompatibility antigen; HLA F antigen; HLAF; HLAF_HUMAN; Leukocyte antigen F; MHC class I antigen F; HLA class I molecule; MHC class Ib antigen; HLA-5.4; HLA-CDA12;
HLA-DOA
major histocompatibility complex, class II, DO alpha
HLA-DOA; major histocompatibility complex, class II, DO alpha; HLA DNA, HLA DZA; HLA class II histocompatibility antigen, DO alpha chain; HLA D0 alpha; HLA class II histocompatibility antigen, DO alpha chain precursor; HLA DNA; HLA DZA; HLADZ; Lymphocyte antigen; Major histocompatibility complex, class II, DN alpha; MHC class II antigen DOA; MHC DN alpha; MHC DZ alpha; HLA-D0-alpha; MHC DN-alpha; HLA-DNA; HLA-DZA;
HLA-DQA2
major histocompatibility complex, class II, DQ alpha 2
HLA-DQA2; major histocompatibility complex, class II, DQ alpha 2; HLA DXA; HLA class II histocompatibility antigen, DQ alpha 2 chain; HLA-DQA1; DX alpha chain; MHC class II DQA2; HLA class II histocompatibility antigen, DQ(6) alpha chain; HLA-DXA; DX-ALPH;
LOC554223
histocompatibility antigen-related
LOC554223; histocompatibility antigen-related; Hypothetical LOC554223; LOC554223 protein;
HM13
histocompatibility (minor) 13
HM13; histocompatibility (minor) 13; minor histocompatibility antigen H13; dJ324O17.1; H13; IMP1; IMPAS; intramembrane protease; presenilin like protein 3; PSENL3; PSL3; signal peptide peptidase beta; signal peptide peptidase like 1; SPP; SPPL1; IMP-1; hI;
H13
histocompatibility 13
H13; histocompatibility 13; minor histocompatibility antigen H13; dJ324O17.1; hIMP1; Histocompatibility (minor) 13; HM13; HM13_HUMAN; IMP-1; IMP1; IMPAS; IMPAS-1; Intramembrane protease 1; Intramembrane protease; Minor histocompatibility antigen 13; MSTP086; OTTHUMP00000030527; OTTHUMP00000030528; OTTHUMP00000030530; OTTHUMP00000214528; Presenilin-like protein 3; PSENL3; PSL3; Signal peptide peptidase; Signal peptide peptidase beta; SPP; presenilin-like aspartyl protease; H-13; AV020344; 1200006O09Rik; 4930443L17Rik; 5031424B04Rik;
H60a
histocompatibility 60a
H60a; histocompatibility 60a; H60; histocompatibility 60; Histocompatibility antigen 60a;
HLA-DRB3
HLA-DRB3 major histocompatibility complex, class II, DR beta 3 [ Homo sapiens ]
major histocompatibility complex, class II, DR beta 3; 4951; MGC117330; DR7; MHC class II antigen DRB3; human leucocyte antigen DRB3; MHC class II HLA-DR beta 3 chain; MHC class II antigen DR beta 3 chain; HLA class II histocompatibility antigen, DR beta 3 chain; HLA class II histocompatibility antigen, DRB1-7 beta chain; HLA-DR3B;
RLA-DR-ALPHA
major histocompatibility complex, class II, DR alpha
RLA-DR-ALPHA;major histocompatibility complex, class II, DR alpha;ENSOCUG00000009103;chromosome: 12;major histocompatibility complex, class II, DR alpha;major histocompatibility complex, class II, DR alpha;
H2-L
histocompatibility 2, D region locus L
H2-L;histocompatibility 2, D region locus L;H-2L;17 19.13 cM;histocompatibility 2, D region locus L;histocompatibility 2, D region locus L;histocompatibility 2, L region;
H2-Aa
histocompatibility 2, class II antigen A, alpha
H2-AA;histocompatibility 2, class II antigen A, alpha;ENSMUSG00000036594;Ia1;H2Aa;Ia-1;H-2Aa;Aalpha;IAalpha;I-Aalpha;17 B1;17 18.65 cM;histocompatibility 2, class II antigen A, alpha;histocompatibility 2, class II antigen A, alpha;A alpha;MHC-II I-A(d) alpha;MHC class II antigen;major histocompatibility protein class II alpha chain;H-2 class II histocompatibility antigen, A-B alpha chain;H-2 class II histocompatibility antigen, A-F alpha chain;H-2 class II histocompatibility antigen, A-K alpha chain;H-2 class II histocompatibility antigen, A-Q alpha chain;H-2 class II histocompatibility antigen, A-R alpha chain;H-2 class II histocompatibility antigen, A-S alpha chain;H-2 class II histocompatibility antigen, A-U alpha chain;
H2-M3
histocompatibility 2, M region locus 3
H2-M3;histocompatibility 2, M region locus 3;ENSMUSG00000016206;Hmt;M3a;R4B2;H-2M3;17 B1;17 20.38 cM;histocompatibility 2, M region locus 3;histocompatibility 2, M region locus 3;MHC class I-b antigen M3;
NCMAP
noncompact myelin associated protein
NCMAP;noncompact myelin associated protein;29332;ENSG00000184454;MP11;C1orf130;1p36.11;FLJ42528;uncharacterized protein C1orf130;uncharacterized protein C1orf130;myelin protein of 11 kDa;
ERGIC1
endoplasmic reticulum-golgi intermediate compartment (ERGIC) 1
ERGIC1;endoplasmic reticulum-golgi intermediate compartment (ERGIC) 1;29205;ENSG00000113719;NET24;ERGIC32;ERGIC-32;5q35.1;FLJ39864, KIAA1181, MGC14345;endoplasmic reticulum-Golgi intermediate compartment protein 1;endoplasmic reticulum-Golgi intermediate compartment protein 1;ER-Golgi intermediate compartment 32 kDa protein;endoplasmic reticulum-golgi intermediate compartment 32 kDa protein;
LOC688090
similar to RT1 class II histocompatibility antigen, B-1 beta chain precursor (RT1.B-beta(1))
HLA-C
HLA-C major histocompatibility complex, class I, C [ Homo sapiens ]
major histocompatibility complex, class I, C; 4933; Ensembl:ENSG00000204525; FLJ27082; HLA class I histocompatibility antigen, Cw-1 alpha chain; MHC class I antigen heavy chain HLA-C; human leukocyte antigen-C alpha chain; major histocompatibility antigen HLA-C; HLA class I histocompatibility antigen, C alpha chain; HLC-C; D6S204; PSORS1; HLA-JY3;
HLA-DPB2
HLA-DPB2 major histocompatibility complex, class II, DP beta 2 (pseudogene) [ Homo sapiens (human) ]
DP2B; DPB2; DPbeta2; HLA-DP2B; HLA-DPB2; major histocompatibility complex, class II, DP beta 2 (pseudogene);
Biosimilar Comparability Studies
As a world leader in biosimilar testing, Creative BioMart provides various analytical assays for physic-chemical and biological properties, which can be applied to demonstrate comparability between production batches of a potentially similar biopharmaceuticals side-by-side with the originator. Ser...
The Company Acquire of Life Technologies Corp
The auction of Life Technologies Corp, which is a genetic testing company, has been attracting more visitors with exception for previous KKR Co LP, Hellman Friedman LLC, Thermo Fisher Scientific Inc,Danaher Corpand a buyout consortium of Blackstone Group LP, private equity firms and so on. Thi...
Protein Localization: Compare the Microscopy-based and Fluorescent Protein Tagging Method
The picture shows the experimentally-determined subcellular localization of almost 500 human proteins using both immunofluorescence and GFP-tagging. Microscopy-based method and fluorescent protein tagging method are two of the most widely used approaches to determine protein localization. But t...
New Hormone Target Clues for Biopharmaceutical Companies
A new research found the effective effect of obesity-against of two hormones in gut, which might be an exciting news for drug companies and individuals who want to keep slim. The two hormones are PYY3-36 and PP. PYY3-36, or Peptide YY(peptide tyrosine tyrosineorpancreatic peptide YY3-36, PYY), is...
Creative BioMart Decided to Enhance Facilities for Biosimilar Comparability Study Services
Creative BioMart, a world leading biotech company that specialized in providing protein, recombinant protein, GMP protein, cell line and protein-related services, decided to enhance its facilities for biosimilar comparability study services. The current guidelines for biosimilar allow a reduced d...
The Brief Inventory of Fines Multinational Pharmaceutical Companies Paid
Following manipulating articles in Journals, GlaxoSmithKline (GSK) entered another trouble time in China. The Public Security Department have begun to investigate its suspicion of commercial bribery, according to Beijing News report, as of July 14, at least four travel ag...
Retrospective Viewpoint: Biotechnology Companies Keep Going with Mergers
In face of patent expiration or other threats, big pharmaceutics are facing challenges too. In priority, innovative technology or novel developments are necessary. On 2010, Celgene declared the acquisition of ABII for $2.9 billion for cancer treatment. ...
Drug Company Concern: Trend in Pharmaceutical Information
On January 3rd, the Public Accounts Committee, British House of Commons published a report with regard to the reservation issue of Tamiflu (a kind of influenza drug that is usually used in the treatment of both seasonal flu and swine flu), which sparked a discussion about...
Big Shuffle in Pharmaceutical Industry: New Round of GMP Certification Creates Chance for Company Acquisition
According to China Food and Drug Administration (CFDA) report, as of December 31, 2013, more than seven hundreds of enterprises in sterile pharmaceutical manufacture in China have approved the newly revised GMP certification, however, more than four ...
Comparing Two Reproductive Cloning Methods: SCNT and iPS
I presumed that many of us still remember the infamous scientific research fraud in 2005, which originated in South Korea when some researchers claimed that they have created human embryonic stem cells via nuclear transfer. Since the geniture of Dolly with somatic cell nuclear transfer (SCNT) in ...
Company Acquisition: VWE International and United Biochemicals
On July 2, VWE International announced that it acquired United Biochemicals, but didnt disclose the deal price. During last year, VWR acquired six labs outside of America, including Vitrium, Sovereign Group,Lab3, Labonord and Switch. VWR finished last year with net income of $3.8 million, ...
One of the Biggest Company Acquisition Cases in Life Science
According to Reuters report, Life Technologies Corp. has accepted the cash acquisition offered by Thermo Fisher Scientific for 13.6 billion on April 15, 2013. So far, the company takeover becomes one of the biggest acquisition cases in life science field. Life Technologies is a biotech tool c...
Company Acquire: Amgen Acquired DeCODE Genetics for $415M Which Is Supposed To Be Closed at the End of 2012
Amgen has planned to acquire Iceland-based DeCODE Genetics which is currently owned by Saga Investments, a consortium including Polaris Venture Partners and ARCH Venture Partners, but later out of bankruptcy in 2010, for $415 million cash, aiming in the biotech pioneers presence in personalized medi...
Company Acquire: In Face with So Many Suitors, Bausch & Lomb Will Belong to Whom?
According to Bloomberg, the private drug and device company Bausch Lomb Company, which is owned by private equity Warburg Pincus, recently was fiercely chased by many giants, such as by Abbott Laboratories (ABT), Johnson Johnson (JNJ), Sanofi and others. Warbur...
The New Round of Worldwide Biotech Companies’ Executives
ImmunoCellular Therapeutics ( $IMUC ) announced Gary S. Titus joined the company's Board of Directors. Titus now works as senior vice president and CFO of SciClone Pharmaceuticals ($SCLN ). Coronado Biosciences ($CNDO) tapped Harlan F. Weisman as the company's new chairma...
Collaboration between Bio Service Provider and Biotech Company on Biospecific Cancer Antibodies
On Jan. 14, 2013, OcellO B.V., providing drug discovery screening services with its 3D cell culture-based screening platform, and Merus B.V., a biotech company, like Creative BioMart , offering specific antibodies and recombinant antibodies to help research, have entered into collaboration....
For Patients’ Good or Company Rival: The Petition of TEVA to FDA on Biogen Idec
Several days ago, Teva Pharmaceutical Industries Ltd, which has the market-leading multiple sclerosis drug Copaxone, handed a petition to the U.S. FDA. In the petition, Teva asked FDA to, if possible, delay the market entry of Biogen Idec Inc.s new MS drug until its safet...
